Navigation Links
Boston Scientific Announces Results For Second Quarter Ended June 30, 2013
Date:7/25/2013

NT OPERATING INCOME*Three Months EndedSix Months EndedJune 30, June 30, in millions20132012**20132012**Segment operating incomeCardiovascular$

194$

195$

364$

386Rhythm Management6177124160MedSurg183150333283Operating income allocated to reportable segments438422821829Corporate expenses and currency exchange

(77)(71)(146)(155)Goodwill and other intangible asset impairment

charges; and acquisition-, divestiture-, restructuring-,

and litigation-related net charges and credits

(40)(3,839)(580)(3,869)Amortization expense(101)(99)(204)(195)Operating income (loss)$220$(3,587)$(109)$(3,390)*We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency and sales from divested businesses.  Sales generated from reportable segments and divested businesses, as well as operating results of reportable segments and corporate expenses, are based on internally-derived standard currency exchange rates, which may differ from year to year, and do not include intersegment profits.  We restated segment information for the prior period based on standard currency exchange rates used for the current period in order to remove the impact of foreign currency exchange fluctuations.  We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-recurring and/or non-operational, such as amounts related to goodwill and other intangible asset impairment charges; acquisition-, divestiture-, restructuring- and litigation-related charges and credits; and amortization expense.  Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation above.** We have restated prior year information to conform t
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. American Laboratory Trading Continues Steady Growth with Expansion in Boston
2. Affordable Scrum Training in Boston,MA by Conscires Agile Practices
3. Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston
4. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
5. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
6. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
7. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
8. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
9. Boston College researchers unique nanostructure produces novel plasmonic halos
10. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
11. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... 21 Cardinal Health, a,global provider of products and ... today announced an order by the New York,Department of ... of,an expanding statewide plan to maintain emergency response readiness, ... Cardinal,Health over the past two years., Cardinal Health ...
... Feb. 21 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... Executive Officer of Trevena, Inc., a privately held,drug discovery ... Directors.,Prior to joining Trevena, Dr. Gowen spent 15 years ... management positions in drug,discovery and development, and led the ...
... Inc.,(Nasdaq: MEDX ) is scheduled to announce ... February 26, 2008 by press release after the,financial ... will host a conference call,and live webcast at ... live, please,dial 1-866-510-0710 (U.S./Canada) or 1-617-597-5378 (international) and,enter ...
Cached Biology Technology:New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 2Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 2Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 3Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 4Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008 2
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... one of the most common and distressing symptoms cancer ... difficult for health care professionals to accurately assess its ... at Chicago are studying fatigue in cancer patients undergoing ... monitor behaviors such as smoking cessation and alcohol use. ...
... companies aren't touting that slogan. At least not yet. , ... Michigan State University professor of chemical engineering and materials science, ... more efficient and cost-effective. , Dale is internationally known ... plant biomass ?the stems, leaves, stalks and trunks of plants ...
... test a revolutionary treatment for blindness in children has ... The trial, funded by the Department of Health, is ... significant impact on future treatments for eye disease. ... have a condition called Leber’s congenital amaurosis (LCA), which ...
Cached Biology News:Cancer patients monitor fatigue in real time 2First clinical trial of gene therapy for childhood blindness 2
... Goat polyclonal to Cholesterol Oxidase ... / Specificity Cross-reacts with bacteria. Not ... Information Cholesterol oxidases exist as both ... are implicated in bacterial pathogenesis. In addition, ...
Phospho-PERK (Thr980) Antibody...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: